DEV Community

Cover image for $3.5B brain chip already lets blind patients read
frank chu
frank chu

Posted on

$3.5B brain chip already lets blind patients read

$3.5B brain chip already lets blind patients read

Science Corporation is worth $3.5 billion after a $400 million Series D — 2.3x its March valuation, eight months after raising $230 million at $1.5 billion. The number that matters more: its PRIMA chip is already CE-marked and restoring form vision in Europe, which makes this the rare brain-computer-interface valuation backed by a shipped product.

The deal, and the math

The facts, from Science's own announcement this morning and TechCrunch: a $400 million Series D, with Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech participating. The $3.5 billion valuation comes from a person familiar with the deal, not from the company — the company confirmed the $400 million and a lifetime total raised of more than $900 million since its 2021 founding. Science was founded by Max Hodak, Neuralink's former president.

The valuation trajectory is the story:

Round Size Post-money valuation Stake sold
Series C, Mar 2026 $230M ~$1.5B ~15.3%
Series D, Nov 2026 $400M $3.5B ~11.4%

That is a 2.33x markup in about eight months, on a round 1.7x the size of the last one — while selling a smaller slice of the company. Two caveats on my arithmetic: the Series C valuation was reported as a range ($1.25B–$1.5B), so 2.33x is the conservative end; at $1.25B the markup would be 2.8x. And the two big rounds sum to $890M against the company's "more than $900M" lifetime figure, so roughly $10M+ came from smaller raises along the way.

What actually ships: PRIMA

PRIMA is a 2×2 mm subretinal implant with 378 light-powered pixels. Camera-equipped glasses project a scene onto the chip, which converts the light into electrical signals that stimulate the retina — a prosthetic for the light-sensitive cells that dry age-related macular degeneration destroys. It is CE-marked in the EU, registered in the UK, and commercially available in Germany. The company says it is now trialling PRIMA for Stargardt's disease, another blindness-causing condition, and is pursuing US approval through the FDA's Humanitarian Device Exemption pathway.

The clinical numbers, from the company's page citing the New England Journal of Medicine (Holz et al., NEJM 2026;394(3):232-242):

  • 80% of patients in the trial showed clinically meaningful improvement in visual acuity at 12 months.
  • 84% reported reading letters, numbers, and words at home with PRIMA at 12 months.
  • Average gain of 25 letters on the eye chart; the best individual improvement was 59 letters — roughly 5 lines and 11 lines respectively.

That is why I take the valuation seriously in a way I would not for a preclinical BCI pitch. The usual brain-chip story is a demo video and a fundraising round. This one has a peer-reviewed trial, a CE mark, and patients reading at home.

The bet the $3.5B is really pricing

PRIMA is the bridge. The moonshot is the biohybrid program: a neural interface that integrates engineered neurons with the brain's own circuits. The company says it is designing initial human trials with Yale neurosurgery professor Murat Günel, with Parkinson's disease named as a potential application.

This is the fork in the BCI road, stated plainly. Neuralink's approach is electrodes in the brain — build the interface out of silicon and metal. Science's long bet is that the interface should be grown, not built: living neurons as the electrode, because biology already knows how to talk to the brain. If that works, it sidesteps the scarring and signal-degradation problems that plague implanted electrodes. If it doesn't, Science is a retinal-implant company that raised $900 million.

That is also what the $3.5 billion is pricing. PRIMA treats geographic atrophy — a real market, but a narrow one, and the US path runs through a humanitarian exemption designed for rare conditions. A $3.5B valuation does not pencil out on a retinal implant for one disease. It pencils out only if investors believe the biohybrid program turns a vision device into a general-purpose brain interface. The valuation doubled in eight months on the back of a European commercial launch; the next doubling, if it comes, depends on neurons in a human brain, not on a chip in an eye.

Two things to watch: reimbursement economics, which the company has not disclosed, and whether the FDA accepts advanced macular degeneration in both eyes as rare enough for the humanitarian pathway — Science says it has convinced the agency, but the approval itself is still ahead. The valuation is a bet on a technology that has not touched a human yet, underwritten by a product that already has.

Sources: TechCrunch, "Science Corporation's brain tech is worth $3.5 billion after new funding" (17 Nov 2026); Science Corporation, Series D announcement; PRIMA product page (trial data, NEJM citation). Valuation figures are per TechCrunch's source; the company confirmed the $400M round size and the >$900M lifetime total.

Top comments (0)